Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
VLDL
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "VLDL" in MCE Product Catalog:
7
7 Publications Verification
別名: AEGR-733 mesylate; BMS-201038 mesylate
Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8 + T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia .
5
Target:
5
5 Cited Publications
Target:
Category:
Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields
Target:
製品番号: HY-P1123
CAS 番号: 87272-20-6
MEDICA16 is an orally active acetyl-CoA carboxylase and ATP-citrate lyase inhibitor. MEDICA16 limits the acetyl-CoA supply for acetyl-CoA carboxylase, inhibits acetyl-CoA carboxylase activity, exerts citrate-competitive inhibitory effects on ATP-citrate lyase, and reduces hepatic AMPK activity. MEDICA16 can be used in research related to insulin resistance, hyperlipidemia, and obesity .
別名: CP-529414
Target:
研究分野:
Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
別名: HOE-402free base
Target:
研究分野:
Imanixil (HOE-402 free base) is an orally active LDL receptor (LDLR) inducer. Imanixil can reduce cholesterol levels by inhibiting VLDL-lipid production. Imanixil can delay atherosclerosis profession. Imanixil can be used for the research of cardiovascular disease, such as atherosclerosis .
製品番号: HY-P990143
製品番号: HY-RS17653
Target:
研究分野:
Cd320 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd320 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
製品番号: HY-106278A
CAS 番号: 343322-50-9
Target:
研究分野:
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
製品番号: HY-112540AR
CAS 番号: 3483-11-2
製品番号: HY-101529R
CAS 番号: 75689-93-9
別名: HOE-402free base (Standard)
Target:
研究分野:
Imanixil (Standard) is the analytical standard of Imanixil (HY-101529). This product is intended for research and analytical applications. Imanixil (HOE-402 free base) is an orally active LDL receptor (LDLR) inducer. Imanixil can reduce cholesterol levels by inhibiting VLDL-lipid production. Imanixil can delay atherosclerosis profession. Imanixil can be used for the research of cardiovascular disease, such as atherosclerosis .
製品番号: HY-N8353
CAS 番号: 149598-71-0
Category:
Target:
製品番号: HY-18778C
CAS 番号: 866399-89-5
別名: TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalcium
研究分野:
Obicetrapib hemicalcium (TA-8995 hemicalcium) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib hemicalcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib hemicalcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. Obicetrapib hemicalcium also exerts a synergistic effect with Ezetimibe (HY-17376) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib hemicalcium can be used in studies related to atherosclerosis and dyslipidemia .
製品番号: HY-P2752A
Target:
研究分野:
Lipoprotein lipase, Bovine (EC 3.1.1.34) belongs to the lipase gene family and is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins (such as those in chylomicrons and very low-density lipoproteins (VLDL)) into two free fatty acid molecules and one monoacylglycerol molecule. Lipoprotein also participates in promoting cellular uptake of chylomicron remnants, cholesterol-rich lipoproteins, and free fatty acids. Lipoprotein requires ApoC-II as a cofactor. Lipoprotein attaches to the luminal surface of capillary endothelial cells via glycosylphosphatidylinositol high-density lipoprotein-binding protein 1 (GPIHBP1) and heparan sulfate proteoglycan.
製品番号: HY-P2752B
Target:
研究分野:
Lipoprotein Lipase, Burkholderia sp. (EC 3.1.1.34) belongs to the lipase gene family and is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins (such as those in chylomicrons and very low-density lipoproteins (VLDL)) into two free fatty acid molecules and one monoacylglycerol molecule. Lipoprotein also participates in promoting cellular uptake of chylomicron remnants, cholesterol-rich lipoproteins, and free fatty acids. Lipoprotein requires ApoC-II as a cofactor. Lipoprotein attaches to the luminal surface of capillary endothelial cells via glycosylphosphatidylinositol high-density lipoprotein-binding protein 1 (GPIHBP1) and heparan sulfate proteoglycan.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
